BioComm Network, Inc. is a strategic communications resource for clients in the biomedical, health advocacy, and alternative energy fields.
Joined September 2012
- Tweets307
- Following0
- Followers96
- Likes72
BioComm Network, Inc retweeted
@AeriePharma receives U.S. FDA approval for its second first-of-a-kind #glaucoma therapy. Proud of our team! bit.ly/2Ci4Jam
BioComm Network, Inc retweeted
Give Sight, Give Delight: Aerie Pharmaceuticals will match attendee donations to @ASCRStweets's charitable programs up to $25,000. Click to donate! buff.ly/2ERaoTm #ASCRSASOA2018 #GiveSight buff.ly/2ERaoTm
BioComm Network, Inc retweeted
Aerie Pharmaceuticals to match @ASCRSFoundation donations during annual @ASCRStweets meeting goo.gl/65z64Z #ASCRS2018 #ASCRSASOA2018
CLICK HERE TO DONATE: ascrsfoundation.org/give
BioComm Network, Inc retweeted
FDA approves Aerie Pharmaceuticals' netarsudil ophthalmic solution 0.02% (Rhopressa) for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension bit.ly/2kHYOSo
BioComm Network, Inc retweeted
Balanced/thoughtful view from Guido Lanza, CEO of Numerate, on AI in drug discovery. No claims of 6 yrs to 6 days! wxpress.wuxiapptec.com/insid…
BioComm Network, Inc retweeted
Trending Topics in the latest ARVONews: New #glaucoma therapies in the works. ow.ly/sCOj30cWMGi
BioComm Network, Inc retweeted
Statement on the US' withdrawal from the Paris climate agreements. #parisagreement
pscp.tv/w/1jMKgoodLyqKL
BioComm Network, Inc retweeted
Alcon Laboratories and CheckedUp expand partnership to educate and engage ophthalmic patients at the point of care bit.ly/2sdL6JQ
BioComm Network, Inc retweeted
Aerie Reports Positive Roclatan (netarsudil/latanoprost ophthalmic solution) Phase 3 Efficacy Results buff.ly/2risviJ #Ophthalmology
BioComm Network, Inc retweeted
FDA accepts Aerie's NDA for netarsudil ophthalmic solution 0.02% (Rhopressa). PDUFA date set Feb. 28, 2018 bit.ly/2ri1R6h
BioComm Network, Inc retweeted
Santen Announces FDA Filing Acceptance of NDA for Intravitreal Sirolimus in the Treatment of Non-Infectious Uveitis buff.ly/2qasmsU
BioComm Network, Inc retweeted
Our cover has been replicated by women surgeons across the world: nyer.cm/9o1oLf0 #NYerORCoverChallenge #ILookLikeASurgeon
BioComm Network, Inc retweeted
Aerie says Rocket 4 phase 3 trial of Rhopressa met primary 3-month efficacy endpoint of noninferiority to b.i.d. timolol. #glaucoma
BioComm Network, Inc retweeted
Rajesh Rajpal, MD, provided update on Avedro. CXL now reality in U.S. There are 14, 000 CXL procedures worldwide - 50% market share. #OISAAO
BioComm Network, Inc retweeted
Avedro is now developing PiXL, a non-invasive procedure to treat low myopia. #OISAAO
BioComm Network, Inc retweeted
Daniel White of Clearside Biomedical outlines its suprachoroidal space microinjector
and clinical data for RVO, uveitis and wet AMD #OISAAO
BioComm Network, Inc retweeted
Retina World Congress releases full meeting agenda for Feb. 23-26, 2017 buff.ly/2dO00Rh #ophthalmology #retina
BioComm Network, Inc retweeted
Clearside to Report Clinical Trial Results from Tanzanite at Retina SubSpecialty Day at #AAO2016 buff.ly/2dqMXD7 #ophthalmology
BioComm Network, Inc retweeted
Read an update from Jason Bacharach, MD, on the clinical development of ROCK inhibitors for #glaucoma treatment: bit.ly/1Xc6Gu4
BioComm Network, Inc retweeted
Mark your calendars for the first inaugural #Retina World Congress Feb 2017 buff.ly/1Z0sVAF #ophthalmology
